Food and Drug Administration's (FDA) 2007 report approving the use of pimobendan for dogs, it stated this conclusion in a four week toxicity study of pimobendan administered to 30 previously healthy lab Beagles: "Conclusions: Pimobendan administered IV daily to healthy Beagles caused dose dependent increases in heart rate, mitral valve myxomatous thickening, left ventricular outflow tract endocardial thickening, and ventricular muscle ischemic lesions (multifocal subendocardial necrosis and scarring)
Of note, many of these cases exhibit CSF oligoclonal bands, Gd-enhancing lesions on MRI and clinical response to immunosuppressionall features very typical of MSindicating that secondary immune responses to a primary trigger can play a significant role in the final clinical phenotype
CYP7A1 was increased in the Augmentin group, showing a reaction to bile flow problems, as noted by Low et al
Specialized cutaneous Schwann cells initiate pain sensation
(2002) Oxidative stress in Portuguese children with Down syndrome
Recalls & Warnings October 18, 2005 FTC Stops False Claims about HGH Oral Spray On October 18, 2005, the Federal Trade Commission (FTC) announced that, at its request, a federal court issued a temporary restraining order against marketers of oral sprays that supposedly contain human growth hormone (HGH) to stop them from making alleged false and deceptive claims and from